Convergence Healthcare Advisors

Convergence Healthcare Advisors is a healthcare-focused investment banking and M&A advisory firm based in Chicago. The firm provides strategic advisory services to healthcare companies, with particular emphasis on medical device manufacturers, diagnostics companies, and healthcare technology providers seeking growth capital, acquisitions, or exit transactions.

The firm's transaction portfolio demonstrates depth in the diagnostics and medical device sectors, having advised on notable deals including Magellan Diagnostics' $66 million sale to Meridian Biosciences, Lumora's dual transactions to Roche and ERBA Diagnostics Mannheim, and Humanscale Healthcare's acquisition by Capsa Healthcare. Their approach combines industry knowledge with transaction structuring expertise, leveraging long-standing relationships with strategic buyers and private equity firms.

Convergence operates as a boutique advisory firm, offering senior-level attention on complex healthcare transactions. Their work spans venture capital, leveraged buyouts, growth capital, and strategic sales across both domestic and international markets.

Choose Convergence Healthcare Advisors when seeking an M&A advisor with specialized expertise in healthcare diagnostics and medical devices who can provide senior-level attention throughout the transaction process. Their established relationships with strategic buyers and private equity firms in the healthcare sector can accelerate deal timelines and improve competitive tension.

Expect a consultative approach that emphasizes strategic positioning and deal structuring. The firm's track record suggests capability in managing both straightforward strategic sales and complex transactions involving technology transfers, international buyers, or staged exits.

Convergence Healthcare Advisors operates exclusively in the healthcare sector, with concentrated expertise in medical devices, in vitro diagnostics, clinical laboratory equipment, and healthcare IT. Their transaction portfolio demonstrates understanding of regulatory pathways (FDA clearances, CLIA waiver), reimbursement dynamics, and the strategic value drivers for clinical products.

The firm's healthcare specialization extends to understanding vertical-specific buyer motivations, from hospital systems seeking workflow solutions to diagnostics companies building test menus and private equity firms executing buy-and-build strategies in healthcare delivery.

The ideal client is a medical device, diagnostics, or healthcare technology company with $10-100 million in revenue, backed by private equity or venture capital investors, seeking strategic alternatives or exit opportunities. Companies with innovative clinical technologies, established customer bases in hospital or physician office settings, and readiness for transaction within 6-12 months will benefit most from Convergence's approach and buyer network.